New data presented at the European Association for the Study of Diabetes (EASD) shows a significantly higher proportion of patients reached target HbA1c levels of <7% when Victoza (liraglutide [rDNA origin] injection) was administrated early in the treatment of type 2 diabetes to patients who had not received treatment before or had previously received only one oral anti-diabetic drug (OAD)...